109 related articles for article (PubMed ID: 16834676)
1. Progress report on phase I/II clinical trial of Ad-OC-TK plus VAL therapy for metastatic or locally recurrent prostate cancer: Initial experience at Kobe University.
Hinata N; Shirakawa T; Terao S; Goda K; Tanaka K; Yamada Y; Hara I; Kamidono S; Fujisawa M; Gotoh A
Int J Urol; 2006 Jun; 13(6):834-7. PubMed ID: 16834676
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer.
Shirakawa T; Terao S; Hinata N; Tanaka K; Takenaka A; Hara I; Sugimura K; Matsuo M; Hamada K; Fuji K; Okegawa T; Higashihara E; Gardner TA; Kao C; Chung LW; Kamidono S; Fujisawa M; Gotoh A
Hum Gene Ther; 2007 Dec; 18(12):1225-32. PubMed ID: 18021019
[TBL] [Abstract][Full Text] [Related]
3. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer.
Kubo H; Gardner TA; Wada Y; Koeneman KS; Gotoh A; Yang L; Kao C; Lim SD; Amin MB; Yang H; Black ME; Matsubara S; Nakagawa M; Gillenwater JY; Zhau HE; Chung LW
Hum Gene Ther; 2003 Feb; 14(3):227-41. PubMed ID: 12639303
[TBL] [Abstract][Full Text] [Related]
4. Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients.
Satoh T; Teh BS; Timme TL; Mai WY; Gdor Y; Kusaka N; Fujita T; Pramudji CK; Vlachaki MT; Ayala G; Wheeler T; Amato R; Miles BJ; Kadmon D; Butler EB; Thompson TC
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):562-71. PubMed ID: 15145177
[TBL] [Abstract][Full Text] [Related]
5. Chemogene therapy: osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model.
Cheon J; Ko SC; Gardner TA; Shirakawa T; Gotoh A; Kao C; Chung LW
Cancer Gene Ther; 1997; 4(6):359-65. PubMed ID: 9408606
[TBL] [Abstract][Full Text] [Related]
6. A pilot study of quality of life of patients with hormone-refractory prostate cancer after gene therapy.
Terao S; Shirakawa T; Acharya B; Miyata M; Hinata N; Tanaka K; Takenaka A; Hara I; Naoe M; Fuji K; Okegawa T; Higashihara E; Kamidono S; Fujisawa M; Gotoh A
Anticancer Res; 2009 May; 29(5):1533-7. PubMed ID: 19443362
[TBL] [Abstract][Full Text] [Related]
7. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer.
Shalev M; Kadmon D; Teh BS; Butler EB; Aguilar-Cordova E; Thompson TC; Herman JR; Adler HL; Scardino PT; Miles BJ
J Urol; 2000 Jun; 163(6):1747-50. PubMed ID: 10799174
[TBL] [Abstract][Full Text] [Related]
8. Thymidine kinase (TK) gene therapy of solid tumors: valacyclovir facilitates outpatient treatment.
Hasenburg A; Tong XW; Rojas-Martinez A; Nyberg-Hoffman C; Kieback CC; Kaplan AL; Kaufman RH; Ramzy I; Aguilar-Cordova E; Kieback DG
Anticancer Res; 1999; 19(3B):2163-5. PubMed ID: 10472325
[TBL] [Abstract][Full Text] [Related]
9. [Gene therapy].
Gotoh A; Shirakawa T; Wada Y; Hinata N; Terao S; Hara I; Arakawa S; Kamidono S; Okada H; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2005 Feb; 51(2):75-9. PubMed ID: 15773357
[TBL] [Abstract][Full Text] [Related]
10. In vivo characterization of a prostate-specific antigen promoter-based suicide gene therapy for the treatment of benign prostatic hyperplasia.
Park HS; Cheon J; Cho HY; Ko YH; Bae JH; Moon DG; Kim JJ
Gene Ther; 2003 Jul; 10(13):1129-34. PubMed ID: 12808443
[TBL] [Abstract][Full Text] [Related]
11. Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients.
Fujita T; Teh BS; Timme TL; Mai WY; Satoh T; Kusaka N; Naruishi K; Fattah EA; Aguilar-Cordova E; Butler EB; Thompson TC
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):84-90. PubMed ID: 16472937
[TBL] [Abstract][Full Text] [Related]
12. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis.
Koeneman KS; Kao C; Ko SC; Yang L; Wada Y; Kallmes DF; Gillenwater JY; Zhau HE; Chung LW; Gardner TA
World J Urol; 2000 Apr; 18(2):102-10. PubMed ID: 10854144
[TBL] [Abstract][Full Text] [Related]
13. Persistent adenovirus-mediated thymidine kinase gene expression in ovarian cancer cells increases cell killing efficacy over time.
Kieback DG; Delvoux B; Romano A; Ollig S; Fischer DC
Anticancer Res; 2008; 28(5A):2569-75. PubMed ID: 19035280
[TBL] [Abstract][Full Text] [Related]
14. Improvement of postherpetic neuralgia after treatment with intravenous acyclovir followed by oral valacyclovir.
Quan D; Hammack BN; Kittelson J; Gilden DH
Arch Neurol; 2006 Jul; 63(7):940-2. PubMed ID: 16682531
[TBL] [Abstract][Full Text] [Related]
15. Elevated activated partial thromboplastin time during administration of first-generation adenoviral vectors for gene therapy for prostate cancer: identification of lupus anticoagulants.
Malaeb BS; Gardner TA; Margulis V; Yang L; Gillenwater JY; Chung LW; Macik G; Koeneman KS
Urology; 2005 Oct; 66(4):830-4. PubMed ID: 16230147
[TBL] [Abstract][Full Text] [Related]
16. Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer.
Ayala G; Satoh T; Li R; Shalev M; Gdor Y; Aguilar-Cordova E; Frolov A; Wheeler TM; Miles BJ; Rauen K; Teh BS; Butler EB; Thompson TC; Kadmon D
Mol Ther; 2006 Apr; 13(4):716-28. PubMed ID: 16480930
[TBL] [Abstract][Full Text] [Related]
17. Herpes virus-associated erythema multiforme following valacyclovir and systemic corticosteroid treatment.
Inoue K; Kano Y; Kagawa H; Hirahara K; Shiohara T
Eur J Dermatol; 2009; 19(4):386-7. PubMed ID: 19482587
[No Abstract] [Full Text] [Related]
18. [Adenovirus-mediated interleukin-12 gene therapy for prostate cancer].
Nasu Y; Ebara S; Kumon H
Nihon Rinsho; 2004 Jun; 62(6):1181-91. PubMed ID: 15206161
[TBL] [Abstract][Full Text] [Related]
19. One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection.
Bavaro JB; Drolette L; Koelle DM; Almekinder J; Warren T; Tyring S; Wald A
Sex Transm Dis; 2008 Apr; 35(4):383-6. PubMed ID: 18362859
[TBL] [Abstract][Full Text] [Related]
20. Symmetrical drug-related intertriginous and flexural exanthema caused by valacyclovir.
Daito J; Hanada K; Katoh N; Katoh S; Sakamoto K; Asai J; Takenaka H; Kishimoto S
Dermatology; 2009; 218(1):60-2. PubMed ID: 18974630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
